

Thomas L Jang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/424241/publications.pdf>

Version: 2024-02-01

27
papers

249
citations

1040056

9
h-index

996975

15
g-index

27
all docs

27
docs citations

27
times ranked

456
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying Publication Rates and Time to Publication for American Urological Association Podium Presentations. <i>Journal of Urology</i> , 2022, 207, 684-691.	0.4	3
2	Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 296-296.e9.	1.9	7
3	Contemporary analysis of cystectomy complications.. <i>Journal of Clinical Oncology</i> , 2022, 40, 473-473.	1.6	1
4	Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. <i>Prostate International</i> , 2022, 10, 75-79.	2.3	7
5	Comparison of perioperative complications for extended vs standard pelvic lymph node dissection in patients undergoing radical prostatectomy for prostate cancer: a meta-analysis.. <i>American Journal of Clinical and Experimental Urology</i> , 2022, 10, 73-81.	0.4	0
6	Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations. <i>BMC Urology</i> , 2022, 22, .	1.4	0
7	Fourteen-Core Systematic Biopsy That Includes Two Anterior Cores in Men With PI-RADS Lesion 3 is Comparable With Magnetic Resonance Imaging-ultrasound Fusion Biopsy in Detecting Clinically Significant Prostate Cancer: A Single-institution Experience. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 275-279.	1.9	1
8	Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 247-257.	1.6	9
9	MicroRNA-371a-3p as a blood-based biomarker in testis cancer. <i>Asian Journal of Urology</i> , 2021, 8, 400-406.	1.2	2
10	Trends in the use of administrative databases in urologic oncology: 2000-2019. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 487-492.	1.6	5
11	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era. <i>Cancer Medicine</i> , 2021, 10, 7909-7920.	2.8	2
12	Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e194-e201.	1.9	10
13	Factors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e643-e650.	1.9	5
14	Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation. <i>Cancer</i> , 2020, 126, 5114-5123.	4.1	11
15	EDITORIAL COMMENT. <i>Urology</i> , 2020, 135, 122.	1.0	0
16	Impact of pathologic lymph node-positive renal cell carcinoma on survival in patients without metastasis: Evidence in support of expanding the definition of stage IV kidney cancer. <i>Cancer</i> , 2020, 126, 2991-3001.	4.1	25
17	Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. <i>Prostate International</i> , 2019, 7, 102-107.	2.3	15
18	Accuracy of clinical nodal staging and factors associated with receipt of lymph node dissection at the time of surgery for nonmetastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 577.e17-577.e25.	1.6	11

#	ARTICLE	IF	CITATIONS
19	Effect of alvimopan on gastrointestinal recovery and length of hospital stay after retroperitoneal lymph node dissection for testicular cancer. <i>Journal of Clinical Urology</i> , 2019, 12, 122-128.	0.1	1
20	Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?. <i>Cancer</i> , 2019, 125, 2318-2320.	4.1	1
21	Multimodal treatments for advanced prostate cancer. <i>Oncotarget</i> , 2019, 10, 255-256.	1.8	0
22	Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 26-32.	1.6	13
23	Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. <i>Cancer</i> , 2018, 124, 4010-4022.	4.1	35
24	Polypoid Endometriosis Presenting as a Renal Cortical Tumor. <i>Urology</i> , 2018, 119, e5-e7.	1.0	5
25	Disparities in the Use of Continent Urinary Diversions after Radical Cystectomy for Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 113-120.	0.4	22
26	Industry Payments to Urologists in 2014: an Analysis of the Open Payments Program. <i>Urology Practice</i> , 2017, 4, 342-348.	0.5	14
27	Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. <i>Frontiers in Oncology</i> , 2017, 7, 107.	2.8	44